Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BEVACIZUMAB-AWWB Cause Disease progression? 160 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 160 reports of Disease progression have been filed in association with BEVACIZUMAB-AWWB. This represents 3.9% of all adverse event reports for BEVACIZUMAB-AWWB.

160
Reports of Disease progression with BEVACIZUMAB-AWWB
3.9%
of all BEVACIZUMAB-AWWB reports
6
Deaths
8
Hospitalizations

How Dangerous Is Disease progression From BEVACIZUMAB-AWWB?

Of the 160 reports, 6 (3.8%) resulted in death, 8 (5.0%) required hospitalization.

Is Disease progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BEVACIZUMAB-AWWB. However, 160 reports have been filed with the FAERS database.

What Other Side Effects Does BEVACIZUMAB-AWWB Cause?

Off label use (441) Product storage error (437) Circumstance or information capable of leading to medication error (346) Hypertension (187) Blood pressure increased (163) Product dose omission issue (158) Adverse event (143) Platelet count decreased (118) Fatigue (104) Intercepted product administration error (97)

What Other Drugs Cause Disease progression?

RITUXIMAB (7,282) CYCLOPHOSPHAMIDE (7,100) DOXORUBICIN (6,165) VINCRISTINE (5,252) PREDNISONE (5,096) BEVACIZUMAB (4,653) DEXAMETHASONE (4,545) CARBOPLATIN (4,538) CAPECITABINE (3,808) ETOPOSIDE (3,776)

Which BEVACIZUMAB-AWWB Alternatives Have Lower Disease progression Risk?

BEVACIZUMAB-AWWB vs BEVACIZUMAB-BVZR BEVACIZUMAB-AWWB vs BEVACIZUMAB-MALY BEVACIZUMAB-AWWB vs BEXAROTENE BEVACIZUMAB-AWWB vs BEZAFIBRATE BEVACIZUMAB-AWWB vs BEZLOTOXUMAB

Related Pages

BEVACIZUMAB-AWWB Full Profile All Disease progression Reports All Drugs Causing Disease progression BEVACIZUMAB-AWWB Demographics